Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
grade D 49.72 3.65% 1.75
BMY closed up 3.65 percent on Tuesday, January 15, 2019, on 1.85 times normal volume.

Earnings due: Jan 24

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical BMY trend table...

Date Alert Name Type % Chg
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 15 Crossed Above 20 DMA Bullish 0.00%
Jan 15 MACD Bullish Signal Line Cross Bullish 0.00%
Jan 14 1,2,3 Retracement Bearish Bearish Swing Setup 3.65%
Jan 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.65%
Jan 14 Narrow Range Bar Range Contraction 3.65%
Jan 14 NR7 Range Contraction 3.65%
Jan 14 NR7-2 Range Contraction 3.65%
Jan 11 Calm After Storm Range Contraction 3.60%
Jan 11 NR7 Range Contraction 3.60%

Older signals for BMY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Is BMY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 70.05
52 Week Low 44.3
Average Volume 12,501,949
200-Day Moving Average 55.3076
50-Day Moving Average 51.3438
20-Day Moving Average 49.3145
10-Day Moving Average 48.142
Average True Range 1.7696
ADX 29.12
+DI 20.3812
-DI 28.222
Chandelier Exit (Long, 3 ATRs ) 48.6262
Chandelier Exit (Short, 3 ATRs ) 49.6088
Upper Bollinger Band 53.0004
Lower Bollinger Band 45.6286
Percent B (%b) 0.56
BandWidth 14.948545
MACD Line -1.0479
MACD Signal Line -1.1213
MACD Histogram 0.0735
Fundamentals Value
Market Cap 81.54 Billion
Num Shares 1.64 Billion
EPS 2.74
Price-to-Earnings (P/E) Ratio 18.15
Price-to-Sales 4.94
Price-to-Book 6.80
PEG Ratio 1.93
Dividend 1.56
Dividend Yield 3.14%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.47
Resistance 3 (R3) 52.20 51.01 52.01
Resistance 2 (R2) 51.01 50.31 51.15 51.85
Resistance 1 (R1) 50.37 49.88 50.69 50.64 51.70
Pivot Point 49.18 49.18 49.35 49.32 49.18
Support 1 (S1) 48.54 48.48 48.86 48.81 47.74
Support 2 (S2) 47.35 48.05 47.49 47.59
Support 3 (S3) 46.71 47.35 47.43
Support 4 (S4) 46.98